|
注册号: Registration number: |
ChiCTR2500097562 |
|
最近更新日期: Date of Last Refreshed on: |
2025-02-20 16:25:50 |
|
注册时间: Date of Registration: |
2025-02-20 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
氢溴酸山莨菪碱注射液对高乳酸型脓毒性休克患者的预后影响:一项前瞻性、多中心、随机、双盲、安慰剂 平行对照临床研究 |
|
Public title: |
Prognostic impact of scopolamine Prognostic impact of scopolamine hydrobromide injection in patients with hyperlactate septic shock: a prospective, multicentre, randomised, double-blind, placebo-parallel controlled clinical studyhydrobromide injection in patients with hyperlactate septic shock |
|
注册题目简写: |
氢溴酸山莨菪碱注射液对高乳酸型脓毒性休克患者的预后影响 |
|
English Acronym: |
Prognostic impact of scopolamine hydrobromide injection in patients with hyperlactate septic shock |
|
研究课题的正式科学名称: |
氢溴酸山莨菪碱注射液对高乳酸型脓毒性休克患者的预后影响:一项前瞻性、多中心、随机、双盲、安慰剂 平行对照临床研究 |
|
Scientific title: |
Prognostic impact of scopolamine hydrobromide injection in patients with hyperlactate septic shock: a prospective, multicentre, randomised, double-blind, placebo-parallel controlled clinical study |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
万峰 |
研究负责人: |
陈德昌 |
|
Applicant: |
Wan Feng |
Study leader: |
ChenDechang |
|
申请注册联系人电话: Applicant telephone: |
+86 136 7803 8143 |
研究负责人电话:
Study leader's |
+86 189 1852 0002 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
13678038143@126.com |
研究负责人电子邮件: Study leader's E-mail: |
chendechangsh@hotmail.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
四川省彭州市天彭镇东三环路二段133号 |
研究负责人通讯地址: |
上海市,瑞金2路197号 |
|
Applicant address: |
133 Second Section, East Third Ring Road, Tianpeng Town, Pengzhou, Sichuan, China |
Study leader's address: |
No. 197 Ruijin 2nd Road, Shanghai 200025 |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
成都第一制药有限公司 |
||
|
Applicant's institution: |
Chengdu First Pharmaceutical |
||
|
研究负责人所在单位: |
上海交通大学医学院附属瑞金医院 |
||
|
Affiliation of the Leader: |
Ruijin Hospital, School of Medicine, Shanghai Jiao Tong University |
||
|
是否获伦理委员会批准: |
是 |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
(2024)临伦审第(7)号 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
上海交通大学医学院附属瑞金医院伦理委员会 |
||
|
Name of the ethic committee: |
Ruijin Hospital Ethics Committee Shanghai Jiao Tong University School of Medicine |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2024-02-02 00:00:00 | ||
|
伦理委员会联系人: |
瞿介明 |
||
|
Contact Name of the ethic committee: |
Qu Jieming |
||
|
伦理委员会联系地址: |
上海市瑞金二路197号 |
||
|
Contact Address of the ethic committee: |
No. 197, Ruijin 2nd Road, Shanghai |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 21 6437 0045 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
|
|
研究实施负责(组长)单位: |
上海交通大学医学院附属瑞金医院 |
||||||||||||||||||||||
|
Primary sponsor: |
Ruijin Hospital, School of Medicine, Shanghai Jiao Tong University |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
上海市瑞金2路197号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
No. 197 Ruijin 2nd Road, Shanghai 200025 |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
成都第一制药有限公司 |
||||||||||||||||||||||
|
Source(s) of funding: |
Chengdu First Pharmaceutical |
||||||||||||||||||||||
|
研究疾病: |
脓毒性休克 |
||||||||||||||||||||||
|
Target disease: |
With septic shock |
||||||||||||||||||||||
|
研究疾病代码: |
|
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
干预性研究 |
||||||||||||||||||||||
|
Study type: |
Interventional study |
||||||||||||||||||||||
|
研究所处阶段: |
上市后药物 | ||||||||||||||||||||||
|
Study phase: |
4 |
||||||||||||||||||||||
|
研究设计: |
随机平行对照 |
||||||||||||||||||||||
|
Study design: |
Parallel |
||||||||||||||||||||||
|
研究目的: |
观察氢溴酸山莨菪碱注射液对高乳酸型脓毒性休克患者预后的影响,为其合理用药提供科学依据。 |
||||||||||||||||||||||
|
Objectives of Study: |
To observe the effect of scopolamine hydrobromide injection on the prognosis of patients with high lactic acid septic shock, and to provide a scientific basis for its rational use. for the rational use of medication. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
|||||||||||||||||||||||
|
Inclusion criteria |
|||||||||||||||||||||||
|
排除标准: |
1: 预后恶劣,如特重型颅脑损伤、心肺复苏术后、恶性肿瘤晚期、严重各 系统疾病终末期 2: 严重快速性心律失常者 3: 已宣布脑死亡者 4: 心源性休克、梗阻性休克、低血容量性休克患者 5: 急性心肌梗死 72h 以内 6: 免疫抑制状态患者:持续使用免疫抑制剂患者;激素使用时间超过 1 个月 7: 排除有粒细胞缺乏症患者 8: 排除颅内压增高、脑出血急性期、前列腺肥大及急性青光眼眼压升高患 者 9: 排除急性胃肠损伤分级评分(AGI)3 级以上患者 10: 排除使用体外膜肺氧合(ECMO)患者 11: 过敏体质,有药物、食物过敏史或已知对本药组成成分过敏者 12: 妊娠或有妊娠计划,哺乳期妇女 13: 合并血液系统疾病者 14: 实体肿瘤未控制状态患者 15: 近 3 个月参加过其它临床试验者 16: 预计生存时间小于 48 小时者; 17: 研究者认为不宜入选的其他原因者。 |
||||||||||||||||||||||
|
Exclusion criteria: |
1: Poor prognosis, e.g., particularly severe craniocerebral injury, post-cardiopulmonary resuscitation, advanced malignant tumour, serious various systemic diseases 2: Severe tachyarrhythmias 3: brain dead 4: Patients with cardiogenic shock, obstructive shock, hypovolaemic shock 5: Acute myocardial infarction within 72h 6: Immunosuppressed patients: patients on continuous immunosuppression; hormone use longer than 1 month 7: Exclusion of patients with granulocyte deficiency 8: Exclusion of patients with increased intracranial pressure, acute phase of cerebral haemorrhage, prostatic hypertrophy and elevated intraocular pressure in acute glaucoma 9: Exclusion of patients with an acute gastrointestinal injury classification (AGI) score of 3 or higher 10: Exclusion of patients using extracorporeal membrane pulmonary oxygenation (ECMO) 11: Allergy, history of drug or food allergy or known allergy to the components of this drug 12: Pregnant or planning a pregnancy, breastfeeding women 13: Combined haematological disorders 14: Patients with uncontrolled solid tumours 15: Participation in other clinical trials in the last 3 months 16: Those with an expected survival time of less than 48 hours; 17: Those with other reasons that the researcher considers inappropriate for enrolment. |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2024-06-01 00:00:00至 To 2027-06-30 00:00:00 |
征募观察对象时间: Recruiting time: |
从 From 2025-02-22 00:00:00 至 To 2027-03-31 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
尚未开始 Not yet recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
中央化随机系统 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
Centralized random system |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
公开/Public |
|
盲法: |
双盲 |
|
Blinding: |
Double blinded |
|
试验完成后的统计结果(上传文件): |
|
|
Calculated Results after
|
|
|
是否共享原始数据: IPD sharing |
否No |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
不共享原始数据 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
NO |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
EDC |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
EDC |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
暂未确定/Not yet |